摘要
目的回顾性观察一线化疗失败后晚期胃癌患者采用不同方案进行二线治疗的疗效及安全性。方法回顾性观察2016年1月至2019年1月就诊于山西省肿瘤医院、采用一线SOX(奥沙利铂+替吉奥)化疗失败后采用不同二线方案治疗的136例晚期胃癌患者的疗效和安全性。结果136例患者中,部分缓解29例,稳定76例,疾病进展31例;客观缓解率为21.3%,疾病控制率为77.2%。在不同治疗方案中,多西他赛联合阿帕替尼的无进展生存期最长,达到4.62个月。结论多西他赛联合阿帕替尼二线治疗晚期胃癌患者可使生存获益,安全性良好。
Objective Review observation was performed on the efficacy and safety of second-line treatment with different regiments in patients with advanced gastric cancer after the failure of first-line chemotherapy.Methods Clinical data of 136 patients with advanced gastric cancer who received first-line SOX(Oxaliplatin+S-1)chemotherapy and failed in Shanxi Cancer Hospital from January 2016 to January 2019 were collected.After treatment with different second-line regimens,the efficacy and safety of the patients were retrospectively reviewed.Results Among 136 patients,29 cases were partial response,76 cases were stable disease,31 cases were progressive disease.The object response rate and disease control rate were 21.3%and 77.2%respectively.Among the different treatments,docetaxel combined with apatinib had the longest PFS,reaching 4.62 months.Conclusion Docetaxel combined with Apatinib in the second-line treatment of patients with advanced gastric cancer has a survival benefit and good safety.
作者
卢宏霞
张宇涛
杨牡丹
高峻
Lu Hongxia;Zhang Yutao;Yang Mudan;Gao Jun(Department of Gastroenterology,Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital,Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University,Taiyuan 030013,China)
出处
《中华转移性肿瘤杂志》
2023年第2期109-113,共5页
Chinese Journal of Metastatic Cancer
关键词
晚期胃癌
阿帕替尼
多西他赛
二线治疗
Advanced gastric cancer
Apatinib
Docetaxel
Second-line treatment
